Regulatory Approval and Commercialization Delays: Ars Pharmaceuticals' success largely depends on obtaining timely regulatory approvals for Neffy in various indications and geographies, and successfully commercializing the product, which could face unforeseen hurdles or delays.

Market Adoption and Competitive Landscape Challenges: Despite regulatory approval, the commercial success of Neffy is not guaranteed and depends on market acceptance, physician prescription, patient adherence, and its ability to compete effectively with existing, established treatments for allergic reactions.

Limited Product Pipeline and Revenue Concentration: The company's current revenue prospects are heavily concentrated on a single product, Neffy, making it highly vulnerable to any issues related to this product's performance, regulatory status, or market reception.